New drug duo aims to slow muscle decline in rare disease

NCT ID NCT06479863

Recruiting now Disease control Sponsor: Austin Neuromuscular Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can improve physical function in people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive the treatment and be monitored for changes in muscle strength and daily activities. The goal is to see if the therapy can help control the disease and ease symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy inclusion body myositis myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHIES SPORADIC INCLUSION BODY MYOSITIS (SIBM)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Austin Neuromuscular Center
RECRUITING

Austin, Texas, 78759, United States
Austin Neuromuscular Center
RECRUITING

Austin, Texas, 78759, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.